Back to Blog

A randomized, blinded, placebo-controlled field study to determine the efficacy and safety of TANOVEA®-CA1 (rabacfosadine for injection) in dogs

Jan 10, 2019

TANOVEA®-CA1 (rabacfosadine for injection) is the first and only FDA conditionally-approved drug for the treatment of lymphoma in dogs. This pivotal study, conducted by VetDC, Inc., is intended to provide the data to demonstrate substantial evidence of effectiveness as well as additional safety information in support of full FDA approval.

Trial Eligibility
VC-014 is a randomized, multi-center, double-blinded, placebo-controlled study evaluating TANOVEA®-CA1 (rabacfosadine for injection) administered every three weeks for up to five treatments in dogs with lymphoma (either previously treated or untreated).

Inclusion/Exclusion Criteria
In order to participate in the study, dogs must meet eligibility criteria described in the protocol. Please contact the study coordinator listed below.

Owner Incentives
The study is fully funded by the Sponsor, and owners will be offered a clinic credit towards additional treatment in the event of disease progression.

Contact Information
Deborah Bascombe, LVT
(203) 838-6626